课题基金 / 基金详情

A small molecule approach to spatial and temporal control of covalent protein inhibition in cells

A small molecule approach to spatial and temporal control of covalent protein inhibition in cells
细胞内共价蛋白抑制的空间和时间控制的小分子方法
批准号:
2883086
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Small molecules that covalently modify proteins are valuable therapeutics and chemical probes for biological discovery. For example, broad-spectrum reactive probes can be used to identify new ligandable sites in proteins that could be targeted by small molecules, and to profile protein modifications that nature uses to modulate protein function. Covalent inhibitors that modify a protein target are an important and growing class of drugs. However, these inhibitors are always "on". The conformations, modifications and locations of proteins in cells are key determinants of biological function, and the goal of this project is to develop a covalent inhibitor that can be switched on in the cell to study the biology of a protein in a defined location and at a specific time. This project will develop chemistry to label protein cysteines in cells using covalent inhibitors with spatial and temporal control. Cysteines are the most frequently targeted residue in covalent inhibitors and are functionally interesting residues that are involved in redox processes and other protein modifications in biology. We will cage cysteine-reactive inhibitors, generating compounds that can enter cells and subsequently be uncaged at a time and place of our choosing to label proteins. This approach would allow us to overcome the potential broad toxicity of covalent probes, and control the time and location (e.g. organelle or tissue) of inhibition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
活细胞单分子成像定量研究EGFR内吞途径命运选择
中性粒细胞在体内条件下重编程为造血干祖细胞的研究
  • 批准号:
    92068101
  • 项目类别:
    重大研究计划
  • 资助金额:
    80.0万元
  • 批准年份:
    2020
  • 负责人:
    程林
  • 依托单位:
小分子化合物促进肝细胞增殖和肝脏再生的研究
  • 批准号:
    32000504
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    郭任
  • 依托单位: